By June 8, 2009, Raptiva will no longer be available in the United States.
Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML).
On 02/19/2009 the FDA issued [...]

Go Back


